Form 4: Fate Therapeutics Director Neelufar Mozaffarian Granted Stock Options

Director Neelufar Mozaffarian of Fate Therapeutics received stock options exercisable for 80,000 shares of common stock.

Summary

• Neelufar Mozaffarian, a director at Fate Therapeutics, was granted stock options on July 29, 2024.
• The options are exercisable for 80,000 shares of Fate Therapeutics' common stock at a price of $5.41 per share.
• The options vest in 36 equal monthly installments, contingent upon Mozaffarian's continued service to the company.
• The options expire on July 29, 2034.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.

Positives

• Granting stock options to directors can align their interests with those of shareholders, incentivizing them to work towards the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant (80,000 shares) would be evaluated relative to the company's market capitalization, the director's role, and industry benchmarks for similar-sized companies.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates